Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,172.00
Ask: 12,174.00
Change: 108.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: FTSE Suffers Worst Fall Of 2014 As Fear Grips Market

Wed, 15th Oct 2014 16:33

LONDON (Alliance News) - UK stock indices closed significantly lower Wednesday, with the FTSE 100 suffering its worst one-day fall of the year so far. The sell-off was mirrored across Europe as markets were gripped by concern about a slowdown in growth amid disappointing economic data from around the world.

Volatility has returned to the markets in a big way, with the VIX volatility index reaching its highest level since since mid-2012, while global bond yields plunged to their lowest levels of the year and gold reached its highest level in more than a month as investors fled to the traditional safe havens.

The FTSE 100 ended the day down 2.8% at 6,211.64, shedding 181 points, which leaves the UK's leading index at its lowest level in 15 months. The mid-cap FTSE 250 ended the day down 1.7% at 14,426.74, and the small-cap AIM All-Share closed down 2.4% at 681.22, its lowest level in almost two years.

Major European equity markets also suffered heavy falls, with the French CAC 40 down a massive 3.6%, and the German DAX 30 down 2.9%. US stocks continued lower, with the DJIA, S&P 500 and Nasdaq Composite all down about 1.5% at the time of the European close. The DJIA slipped below 16,000 for the first time since February.

European indices started lower Wednesday amid ongoing concerns over the health of the eurozone economy, after early data from Germany showed consumer prices stagnated in September, for the second consecutive month. Those concerns were only compounded by continued declines in the price of oil, with Brent crude hitting a near four-year low in early trade, bottoming at USD83.35 per barrel.

Investors also remain concerned over the spread of Ebola, after a second healthcare worker in the US was confirmed to have caught the virus. The infected person was on an internal US flight on Monday night, and authorities are looking to contact the other passengers on the flight.

Global indices unwound further in afternoon trade after some disappointing US economic data showed retail sales there fell by 0.3% month-on-month in September, exceeding expectations for a 0.1% fall. The New York manufacturing index also contracted sharply in September, coming in at 6.17, down from 27.54 in August, while US producer price growth also turned negative, recording a month fall of 0.1%. The apparent slowing in US economic activity comes as a particular concern to investors given that it coincides with the end of the Federal Reserves quantitative easing programme later this month.

In London, Shire led the FTSE 100 lower from the outset Wednesday, plunging by a quarter at the open after US authorities appeared to get their way when AbbVie Inc said it is reconsidering its takeover of the Irish drug maker. The deal, which valued Shire at GBP32 billion, had been thrown into some doubt after US Treasury Secretary Jack Lew announced new measures last month to make so-called tax inversion deals less appealing. The news that AbbVie actually has gotten cold feed still took the markets by surprise, and Shire ended the day heavily lower at GBP39.43, not far from its mid-June price, when it originally rejected an advance from AbbVie.

Oil stocks were weighed down by oil prices, with Tullow Oil dropping 4.7%, Royal Dutch Shell falling 2.3%, Enquest down 5.7%, and Cairn Energy down 3.3%. BG Group held up relatively well against the sector decline, ending down just 0.5% after announcing that it poached Helge Lund from Norwegian rival Statoil to be its new chief executive from next March. Deutsche Bank sees the appointment as a positive step for BG, calling Lund an "industry heavyweight". Separately, BG Group said it had started production on the Iracema area in block BM-S-11 in the Santos Basin offshore Brazil early.

Royal Mail was the only FTSE 100 stock to record any significant gains, significantly outperforming the market and closing up 1.9% following the news Tuesday that it has sold one of its sites that is "recognised a surplus" for GBP111 million. Analysts at Berenberg say that the sale price was 85% above its own valuation, therefore indicating that Royal Mail shares may be significantly undervalued.

FTSE 250 listed CSR surged 30% after the semiconductor producer said it agreed to be acquired by US-based semiconductor company Qualcomm Inc for GBP1.6 billion in cash, a deal that comes after it has been in talks about a potential takeover with Microchip Technology Inc since August. The 900 pence a share bid from the US semiconductor group comes after CSR rebuffed an approach from Microchip Technology for being too low in August.

Balfour Beatty rose 11% on the news that it has poached the chief executive of defence products company QinetiQ Group to be its own CEO from January 1, 2015, a job that will involve turning the struggling company around after a string of profit warnings, a failed merger attempt from rival Carillion, and the disputed sale of its US project management business. Analysts have been positive over the appointment of new CEO Leo Quinn. Jefferies says he has a good track record as a turnaround specialist. QinetiQ was the worst performer in the FTSE 250, closing down 12%.

The most positive economic news of the day came from the UK Wednesday, where the unemployment rate fell to a six year low of 6.0% in August from 6.2% in July, exceeding expectations for a fall to 6.1%. Average earnings also improved a little faster that expected, rising by 0.9% in August, up from 0.8% in July and beating the expectation for the growth rate to remain unchanged.

A combination of the better UK data and weakness in the US dollar after the poor data across the pond sent the currency pair briefly back above USD1.60, although at the time of the equity market close the pound has weakened again to trade at USD1.5955.

Safe haven demand sent gold up to its highest level in more than a month, peaking at USD1,249.61 per ounce. The firmer price provided support for precious metal miner Fresnillo, which closed up 0.4% after raising its 2014 gold production target to 590,000 ounces.

There may be more volatility still to come Wednesday, with European Central Bank President Mario Draghi due to speak at 1900 BST from an International Monetary Fund event in Washington. The Federal Reserve's Beige Book of economic conditions is also due to be released at the same time.

Looking towards Thursday, eurozone consumer inflation data will be the morning focus, while from the US in the afternoon there is a raft of data including jobless claims and industrial production, as well as a number of speeches from Fed officials.

In the UK corporate calendar Thursday, drinks giant Diageo is due to make an interim management statement, as are Evraz, Mondi, and Man Group, among others. British Sky Broadcasting is due to release first-quarter results.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.